logo

Xortx Therapeutics Inc (XRTX)



Trade XRTX now with
  Date
  Headline
1/19/2023 7:08:06 AM XORTX Announces Positive Topline Results From XRX-OXY-101 Clinical Trial
11/16/2022 7:08:29 AM XORTX Therapeutics Appoints Stacy Evans As Chief Business Officer
8/22/2022 8:20:33 AM XORTX Announces Positive Topline Results From Part 2 Pharmacokinetics Bridging Study
7/13/2022 7:07:04 AM XORTX Announces Positive Topline Results From Pharmacokinetics Bridging Clinical Trial
7/7/2022 7:09:55 AM XORTX Announces Pre-Phase 3 Meeting Request With US FDA
4/12/2022 7:10:13 AM XORTX Receives No Objection Letter From Health Canada For XRX-OXY-101 Clinical Bridging Pharmacokinetics Study
1/13/2014 11:04:46 AM Xyratex Ltd (XRTX) Declares Quarterly Dividend of $ 0.075, Record Date 2/4/2014
10/3/2013 9:15:47 PM Xyratex Ltd (XRTX) Declares Quarterly Dividend of $ 0.075 , Record Date 10/17/2013
4/4/2013 4:03:12 PM Xyratex Ltd (XRTX) Declares Quarterly Dividend of $ 0.075 , Record Date 4/18/2013
12/17/2012 5:47:51 PM Xyratex Ltd (XRTX) Declares Special Dividend of $ 2.00, Record Date 12/27/2012
10/2/2012 4:08:17 PM Xyratex Ltd (XRTX) Declares Quarterly Dividend of $ 0.075, Record Date 10/16/2012
7/5/2012 4:09:15 PM Xyratex Ltd (XRTX) Declares Quarterly Dividend of $ 0.075, Record Date 7/19/2012
3/30/2012 12:48:34 PM RBC Capital Markets Is Raising Xyratex Ltd (XRTX) 2012 Estimate To 1.42 From 1.40
3/30/2012 12:48:25 PM RBC Capital Markets Is Lowering Xyratex Ltd (XRTX) Q4 12 Estimate To 0.35 From 0.40
3/30/2012 12:48:13 PM RBC Capital Markets Is Lowering Xyratex Ltd (XRTX) Q3 12 Estimate To 0.36 From 0.45
3/30/2012 12:48:00 PM RBC Capital Markets Is Lowering Xyratex Ltd (XRTX) Q2 12 Estimate To 0.31 From 0.34
3/30/2012 12:47:19 PM RBC Capital Markets Is Lowering Xyratex Ltd (XRTX) 2012 Rev. Estimate To 1.30 Billion From 1.38 Billion